Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Study Of Docetaxel + Pf 03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer

NCT01876251 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01876251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01876251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Study Of Docetaxel + Pf 03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
November 4, 2013
Completion date
December 24, 2015
Enrollment
30 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic